Quotient Clinical extends spray drying capabilities for poorly soluble molecules

Quotient Clinical, the Translational Pharmaceutics® company, has expanded its clinical spray drying capability through the acquisition of a Niro Mobile Minor™ Spray Dryer.

Quotient has a proven track record of developing spray-dried dispersions to overcome drug compound solubility issues, and the addition of a larger scale spray dryer will allow the production of a range of batch sizes, from milligrams up to two kilograms.

Sited at Quotient’s new GMP facility at MediCity in Nottingham, UK – scheduled to open later in 2016 – this expansion is a direct response to customer requests for ongoing product development support, including toxicology and later stage clinical studies.

Nikki Whitfield, VP of Pharmaceutical Sciences, commented:

“Poor solubility is increasingly prevalent in drug pipelines across the industry. We have established a broad suite of formulation approaches within our Translational Pharmaceutics platform to address these complex solubility and bioavailability challenges, and this latest investment will allow us to efficiently scale up the production of optimised formulations to support our clients’ downstream clinical development programs.”